Vanguard Group
KROS icon

Vanguard Group’s Keros Therapeutics KROS Stock Holding History

Vanguard Group’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$31.1M Sell
1,525,355
-1,193,422
-44% -$20.9M ﹤0.01% 2422
2025
Q3 		$43M Buy
2,718,777
+87,129
+3% +$1.29M ﹤0.01% 2234
2025
Q2 		$35.1M Buy
2,631,648
+65,327
+3% +$882K ﹤0.01% 2289
2025
Q1 		$26.2M Buy
2,566,321
+609,212
+31% +$7.07M ﹤0.01% 2384
2024
Q4 		$31M Buy
1,957,109
+100,691
+5% +$5.23M ﹤0.01% 2374
2024
Q3 		$108M Buy
1,856,418
+99,298
+6% +$4.9M ﹤0.01% 1839
2024
Q2 		$80.3M Buy
1,757,120
+211,362
+14% +$11.4M ﹤0.01% 1941
2024
Q1 		$102M Buy
1,545,758
+113,563
+8% +$6.73M ﹤0.01% 1859
2023
Q4 		$56.9M Buy
1,432,195
+25,764
+2% +$808K ﹤0.01% 2129
2023
Q3 		$44.8M Buy
1,406,431
+222,652
+19% +$8.31M ﹤0.01% 2182
2023
Q2 		$47.6M Buy
1,183,779
+135,717
+13% +$5.95M ﹤0.01% 2206
2023
Q1 		$44.8M Buy
1,048,062
+2,742
+0.3% +$138K ﹤0.01% 2221
2022
Q4 		$50.2M Buy
1,045,320
+138,746
+15% +$6.48M ﹤0.01% 2185
2022
Q3 		$34.1M Buy
906,574
+134,956
+17% +$4.68M ﹤0.01% 2374
2022
Q2 		$21.3M Buy
771,618
+35,025
+5% +$1.54M ﹤0.01% 2608
2022
Q1 		$40.1M Buy
736,593
+2,873
+0.4% +$147K ﹤0.01% 2413
2021
Q4 		$42.9M Buy
733,720
+23,959
+3% +$1.19M ﹤0.01% 2438
2021
Q3 		$28.1M Buy
709,761
+41,558
+6% +$1.48M ﹤0.01% 2665
2021
Q2 		$28.4M Buy
668,203
+65,557
+11% +$3.55M ﹤0.01% 2659
2021
Q1 		$37.1M Buy
602,646
+10,391
+2% +$658K ﹤0.01% 2468
2020
Q4 		$41.8M Buy
592,255
+293,324
+98% +$18.5M ﹤0.01% 2294
2020
Q3 		$11.5M Sell
298,931
-13,476
-4% -$534K ﹤0.01% 2721
2020
Q2 		$11.7M Buy
+312,407
New +$9.62M ﹤0.01% 2688

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group's KROS Position: Q4 2025 in Review

Vanguard Group reduced its Keros Therapeutics (KROS) stake by 44% in Q4 2025, selling an estimated $20.9M and leaving 1,525,355 shares worth $31.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2422.

Vanguard Group first reported a position in KROS in Q2 2020 and has held it in 23 quarters since. The position peaked at $108M in Q3 2024. 166 funds tracked by Wall St. Rank hold KROS as of Q4 2025.

  • Vanguard Group held 1,525,355 shares of Keros Therapeutics worth $31.1M as of Q4 2025.
  • Vanguard Group sold 1,193,422 Keros Therapeutics shares in Q4 2025, an estimated $20.9M.
  • Keros Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2422 holding.
  • Vanguard Group first reported a position in Keros Therapeutics in Q2 2020 and has held it in 23 quarters since.
  • Vanguard Group's Keros Therapeutics position peaked at $108M in Q3 2024.
  • 166 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.